CEL SCI Corp (CVM) stock
CVMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$1.19−0.12 (-9.16%)
Close on Nov 12, 2026Market cap $20.93MP/E –Yield –
Cel Sci total assets
Total assets on the balance sheet at the end of each period.
Cel Sci's total assets was $21.36M at Jun 30, 2026. For fiscal 2025 it was $28.16M, up 4.3% from the year before. Over ten years it grew -0.1% a year on average. The highest annual figure on record is $75.87M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $28.16M | +4.3% |
| FY2024 | Sep 30, 2024 | $26.99M | -11.6% |
| FY2023 | Sep 30, 2023 | $30.53M | -39.6% |
| FY2022 | Sep 30, 2022 | $50.52M | -33.4% |
| FY2021 | Sep 30, 2021 | $75.87M | +87.2% |
| FY2020 | Sep 30, 2020 | $40.54M | +46.7% |
| FY2019 | Sep 30, 2019 | $27.62M | -6.6% |
| FY2018 | Sep 30, 2018 | $29.59M | +29.1% |
| FY2017 | Sep 30, 2017 | $22.92M | -7.9% |
| FY2016 | Sep 30, 2016 | $24.89M | -12.8% |
| FY2015 | Sep 30, 2015 | $28.55M | +48.5% |
| FY2014 | Sep 30, 2014 | $19.23M | +77.4% |
| FY2013 | Sep 30, 2013 | $10.84M | -32.5% |
| FY2012 | Sep 30, 2012 | $16.07M | -13.7% |
| FY2011 | Sep 30, 2011 | $18.63M | -50.7% |
| FY2010 | Sep 30, 2010 | $37.80M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $21.36M | +5.0% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $17.71M | -18.8% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $22.89M | -10.9% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $28.16M | +4.3% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $20.34M | -15.5% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $21.81M | -27.4% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $25.70M | -10.5% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $26.99M | -11.6% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $24.07M | -25.5% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $30.05M | -21.3% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $28.71M | -35.6% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $30.53M | -39.6% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $32.32M | -43.2% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $38.20M | -40.5% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $44.56M | -36.0% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $50.52M | -33.4% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $56.89M | -28.6% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $64.16M | +32.7% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $69.67M | +40.4% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $75.87M | +87.2% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $79.64M | +81.4% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $48.37M | +32.0% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $49.61M | +57.5% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $40.54M | +46.7% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $43.91M | +54.1% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $36.65M | +48.0% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $31.49M | +21.4% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $27.62M | -6.6% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $28.48M | +31.3% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $24.76M | +7.2% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $25.93M | +17.0% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $29.59M | +29.1% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $21.70M | -0.6% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $23.09M | +4.6% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $22.17M | -4.6% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $22.92M | -7.9% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $21.82M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $22.08M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $23.25M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $24.89M | – |
See a number that looks wrong?